Abstract: The invention relates to a process for producing a compound comprising the anion [CF218FSO2]?, which process comprises treating a difluorocarbene source with (i) a source of 18F? and (ii) a source of SO2. The invention relates to a compound which comprises that anion. The invention also relates to the use of the compound comprising the anion [CF218FSO2]? to produce a compound comprising an 18F-trifluormethyl functionalised aromatic group. Compounds comprising an 18F-trifluoromethyl functionalised aromatic group are also the subject of the present invention.

Abstract: There is provided herein an anode for a magnetron, the anode comprising: a cylindrical shell defining a longitudinal axis, a centre of the shell for accommodating a cathode of the magnetron; a plurality of vanes arranged at angular intervals around the shell, wherein an angular separation between each vane and its adjacent vane is configured to provide a cavity resonator of the magnetron, wherein each vane has a width extending radially inwardly from the shell toward the centre of the shell, and has a length continuously extending longitudinally in parallel with the longitudinal axis of the shell; and a plurality of annular strap rings for setting a resonant mode spectrum of the cavity resonator, wherein the strap rings are arranged at longitudinal intervals and concentrically with the longitudinal axis of the shell, wherein each vane comprises an inner vane segment arranged to face the cathode and a respective outer vane segment connected to the inner vane segment and interposed between the inner vane segmen

Abstract: A system includes at least one hardware processor and a memory storing instructions that, when executed by the at least one hardware processor, cause the at least one hardware processor to perform operations including identifying a component of tracked conduct, the component of tracked conduct including a first conduct trigger condition and a reward, the first conduct trigger condition is associated with conduct of a user related to retirement, receiving conduct data associated with the first conduct trigger condition from a first data source, determining, using the conduct data, that the first conduct trigger condition is satisfied, and causing the reward to be provided to the user.

Abstract: There is described a method of determining a reactive torque factor for use in controlling a toolface of a downhole tool. For each of one or more sliding operations, a change in a top drive position of a drive unit operable to rotate a drill string connected to the downhole tool is determined, a change in a toolface of the downhole tool is determined, and a change in a differential pressure is determined. Based on the change in the top drive position, the change in the toolface, and the change in the differential pressure, a reactive torque factor is determined.

Abstract: This invention relates to a breath indicator for providing an indication of an inhalation and/or exhalation state of a user. Said breath indicator comprising a body comprising a gas sampling portion configured for receipt of a user's inhalation and/or exhalation gases, and an indicator portion. Said gas sampling portion in fluid communication with said indicator portion. Said indicator portion comprising at least a first region and at least a second region, the first region comprising a gas parameter detecting material capable of changing between an initial visual state and a subsequent visual state indicative of detection of a gas parameter of inhalation and/or exhalation gases of said user; and wherein said initial visual state and/or said subsequent visual state of the first region visually contrasts with a visual state of at least said second region.

Abstract: A polymeric material for use in thermal insulation is provided. The polymeric material is formed from a thermoplastic composition containing a continuous phase that includes a matrix polymer and within which a microinclusion additive and nanoinclusion additive are dispersed in the form of discrete domains. A porous network is defined in the material that includes a plurality of nanopores having an average cross-sectional dimension of about 800 nanometers or less. The polymeric material exhibits a thermal conductivity of about 0.20 watts per meter-kelvin or less.

Abstract: Disclosed herein are genetically engineered hematopoietic cells (e.g., genetically engineered hematopoietic stem cells, or genetically engineered immune cells), which co-express one or more co-stimulatory polypeptides with an anti-GPC3 chimeric antigen receptor (CAR), and uses thereof for enhancing T cell anti-tumor activity in a subject in need of the treatment.

Abstract: This invention relates to a patient interface, such as a nasal cannula, comprising a body to be positioned upon a user (preferably such as a user's face), the body including at least one (and preferably a pair of) nasal prong(s), the or each nasal prong including a lumen capable of being fluidly connected thereto for fluid communication with a supply of breathable gas, the or each nasal prong to be in a configuration either inserted into, or to direct a flow of gas toward, a nare or the nares of the user's nose, wherein the body includes at least one element responsive to force(s) or movement(s), or both, experienced by at least a first region of the patient interface.

Abstract: A patient interface, such as a nasal cannula is described. The patient interface has a body portion to be located, in-use upon a face of a user. The body portion has at least one side arm that extends laterally from a central bridge portion to be located about a user's septum region, where each side arm is connected to a resilient, or relatively more rigid, bridge portion element. The interface has at least one, and preferably a pair of, nasal prong(s). The body portion has at least one fluid passageway connected to the nasal prong(s) for supply of a gas to the nare(s) of the user's nose. A cross section of the passageway varies along the length of the body portion to regions of varying flexibility along the body portion. The bridge portion element defines a substantially predetermined spatial relationship for outlet(s) of a gas delivery system supplying gas via each side arm to the outlet(s) from which, for example, the nasal prong(s) may be provided in fluid connection.

Abstract: Disclosed herein are genetically engineered hematopoietic cells, which express one or more lactate-modulating factors (e.g., polypeptides), and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

Abstract: Bulk catalysts comprised of nickel, molybdenum, tungsten and titanium and methods for synthesizing bulk catalysts are provided. The catalysts are useful for hydroprocessing, particularly hydrodesulfurization and hydrodenitrogenation, of hydrocarbon feedstocks.

Abstract: Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Abstract: The present invention relates to radiolabelled olaparib and in particular [18F]olaparib, a process for producing radiolabelled olaparib, and uses of radiolabelled olaparib in medical imaging.

Abstract: There is described a method for automatically controlling a drilling operation. The method comprises obtaining a recording of one or more controlled drilling parameters adjusted, during a first drilling operation, in response to one or more controlling drilling parameters. The method further comprises, during a second drilling operation subsequent to the first drilling operation, monitoring the one or more controlling drilling parameters. The method further comprises, during the second drilling operation, automatically adjusting the one or more controlled drilling parameters in response to the monitored one or more controlling drilling parameters by using the recording of the one or more controlled drilling parameters. Thus, by recording a driller's instructions once (during a recording phase) and automatically replaying them during successive playback phases, drilling is made more efficient and simpler.

Abstract: This invention relates to a patient interface, such as a nasal cannula, including a body to be positioned upon a user (preferably such as a user's face), the body including at least one (and preferably a pair of) nasal prong(s), the or each nasal prong including a lumen capable of being fluidly connected thereto for fluid communication with a supply of breathable gas, the or each nasal prong to be in a configuration either inserted into, or to direct a flow of gas toward, a nare or the nares of the user's nose, wherein the body includes at least one element responsive to force(s) or movement(s), or both, experienced by at least a first region of the patient interface.

Abstract: Disclosed herein are genetically engineered immune cells, which express one or more glucose importation polypeptides and optionally a chimeric receptor polypeptide, for example, an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide. Also disclosed herein are uses of such genetically engineered immune cells for inhibiting cells expressing a target antigen in a subject in need of the treatment, either taken alone or in combination with an Fc-comprising agent (e.g., an antibody) that binds the target antigen.

Abstract: A patient interface, such as a nasal cannula is described. The patient interface has a body portion to be located, in-use upon a face of a user. The body portion has at least one side arm that extends laterally from a central bridge portion to be located about a user's septum region, where each side arm is connected to a resilient, or relatively more rigid, bridge portion element. The interface has at least one, and preferably a pair of, nasal prong(s). The body portion has at least one fluid passageway connected to the nasal prong(s) for supply of a gas to the nare(s) of the user's nose. A cross section of the passageway varies along the length of the body portion to regions of varying flexibility along the body portion. The bridge portion element defines a substantially predetermined spatial relationship for outlet(s) of a gas delivery system supplying gas via each side arm to the outlet(s) from which, for example, the nasal prong(s) may be provided in fluid connection.

Abstract: The present invention relates to an isolated specific binding molecule which binds human Anx-A1 and comprises the complementarity-determining regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, wherein each of said CDRs has an amino acid sequence as follows: VLCDR1 has the sequence set forth in SEQ ID NO: 1, 36 or 37; VLCDR2 has the sequence set forth in SEQ ID NO: 2; VLCDR3 has the sequence set forth in SEQ ID NO: 3; VHCDR1 has the sequence set forth in SEQ ID NO: 4; VHCDR2 has the sequence set forth in SEQ ID NO: 5; and VHCDR3 has the sequence set forth in SEQ ID NO: 6; or, for each sequence, an amino acid sequence with at least 85% sequence identity thereto. The specific binding molecule disclosed is therapeutically useful and in particular may be used in therapy for T-cell mediated diseases, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, obsessive compulsive disorder (OCD), and OCD-related diseases, such as anxiety disorders.